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Furthermore, the fruits of Terminalia chebula are also used in India for curing a host of ailments, such as hemorrhoids and cirrhosis of the liver with ascites. Also, the fruits of Terminalia chebula form one of the components of the "galenical" called Triphala, which was reported as a highly effi cacious cardiotonic.³ Based on purely anecdotal data, the use of folk remedies and their successful implementation by Indian physicians who avail themselves of folk remedies may be helpful for their patients. However, anecdotal data do not meet the regulatory requirement of "based on human experience." Th e method they chose would not be well received by either the USEPA or by USFDA because tier testing has never been an acceptable substitute for required animal testing. Secondly, purely anecdotal data have always been eschewed by both agencies.
In the article "Evaluation of genotoxicity of medicinal plant extracts by the comet and the Vitotox® test," the authors demonstrate that the tier testing they performed shows that these materials do not present a carcinogenic risk. Explicit animal testing data on the active principles contained in the extract are not enough to satisfy the requirement. Accurate dose response data in people are needed to meet the "based-on-human-experience" regulation. Th e authors assert that there is a plethora of anecdotal data on these materials used by people practicing folk medicine in India. To be useful, the data must be centered on the action of the active principle(s) and on enough people in diff erent identifi able cohorts.
Th ere are two approaches that regulatory agencies such as the EPA and the FDA would not object to when it comes to foregoing the usual battery of animal testing. Th ey are titled "on the basis of human experience." One approach is to use epidemiology data, which by their very nature are based on human exposures. Th e second approach is to present a complete set of comparative human and animal pharmacologic data, including the metabolites of the active principle. Th ese two sets of experiments need to be performed using drugs that have been given to human patients by folk doctors as well as by traditional medical practitioners in India, in order to demonstrate that the concept "on the basis of human experience" was fulfi lled. What is usually not available is the actual dosage used and data on which of the isolates is the active principle of the extracts. Today, it is easier to chemically defi ne the active principle of chemical mixtures and extracts given the major advances in synthetic organic chemical apparatus. Also missing is the set of experiments that defi ne the metabolites that human subjects produce when taking the active principle in question. Th is too has become much less diffi cult for the same reasons.
Once the chemical information is developed on commonly administered extracts, one could design a set of studies that side-steps much of the required animal testing. If the human data were available on the toxicity potential posed by chronic exposure, it might be possible to eliminate much of the long-term animal testing step. Similar data would eliminate the need for initial human testing, saving hundreds of thousands of dollars, but, more importantly, would add at least three years to the drug(s) patent usefulness.
An epidemiological approach would suffi ce if the actual doses were known and acceptable cohorts developed. As in most successful epidemiological studies, there would have to be stratifi cation based on dose, age, and gender. An example would be to determine the following information on drugs that aff ect hormone levels in women: Do women on this drug experience diffi culty in attaining and maintaining pregnancy? What percentage of the drug reaches the developing fetus before the development of a placenta? What happens to the fetus when exposed to the chemical during the fi rst trimester? All the above could be answered if a cohort of women who intend to take this drug during pregnancy were followed to term.
Another approach would be for drugs that do not change hormonal activity. In this case, parallel studies would have to be designed in which the principles of the native drug(s) and the "galenicals" are administered to diff erent cohorts simultaneously and the regression line of the desired eff ect is compared. If the line does not diff er from parallel, then we are indeed testing an active principle.
When the epidemiology studies are completed, it should be possible to say that the researchers have developed enough data to obtain a permit for an investigational new drug (IND) and for human testing to begin. Actual human data are far more desirable than animal data when the eff ects of the compound are known to be benefi cial and a history of human use is well documented.
LD₅₀ experiments must be performed on laboratory animals to establish the cause of death from overdose and whether there is a small or large margin of safety. If the material is toxic at some level (as is almost always the case for biologically active compounds), we need to know the level and the actual cause of death. Th e margin of safety would have to be suffi cient that these levels will never be approached under normal clinical conditions.
Th ese are the kinds of human data sets that would accomplish what the authors were attempting. It is possible to side-step and eliminate most-but not all-long-term animal testing with suffi ciently high-quality human data. Th e availability of human data could reduce the time-frame required for approval if all the studies went as planned and the drugs were as safe and effi cacious as fi rst thought. In my experience, a set of experiments as complicated as these always has pitfalls. However, a signifi cant advantage with the savings of cost and time can be accomplished. Tier testing was never meant to provide information necessary to allow testing of the compounds as drugs.
Each uniquely biologically active chemical used in folk medicine presents a separate set of problems that need to be addressed. Th at does not mean that data development must start from scratch. It is just that bacteriological testing of these chemicals cannot be used in place of whole animal tests. Proper design of human cohorts can answer many of the questions that animal testing attempts and with far more useful data.
Compounds known to produce desired therapeutic outcomes are always preferred to compounds thought to have these properties. Successful approaches such as the ones outlined above should encourage researchers to fi nd these native and folk medicines, chemically characterize the active principles, and bring them into the modern armamentarium of therapeutic drugs.
